Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. filings document foreign private issuer reporting for a Nasdaq-listed ADS issuer operating biopharmaceutical R&D and CDMO businesses. Form 6-K reports furnish current information on material agreements, clinical and regulatory disclosures for PC111 and related immunology programs, Nasdaq minimum bid price notices, capital-structure matters, and incorporation of current reports into Form F-3 and Form S-8 registration statements.
The filing record also documents the completed acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., including audited subsidiary financial statements and unaudited pro forma consolidated and combined financial information. Proxy and governance filings cover annual general meeting materials, ADS voting procedures, board composition changes, auditor selection, risk factors, and shareholder voting matters.
Scinai Immunotherapeutics Ltd. (SCNI) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq notified the company that, for 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai’s American Depositary Shares was at or above $1.00, and the prior deficiency matter is now closed.
The company states that, with this listing issue resolved, it remains focused on commercial execution at its Scinai Biopharma Services CDMO business and on advancing its NanoAb immunology therapy programs developed under collaborations with the Max Planck Society and University Medical Center Göttingen.
Scinai Immunotherapeutics Ltd. (SCNI) reports a strategic shift after its option and license arrangements with PinCell for the preclinical program PC111 expired on August 31, 2026 and terminated according to their terms, with no new extension agreed.
Scinai is reallocating R&D resources toward its NanoAb platform and preserving capital and management capacity to support growth of Scinai Biopharma Services, its CDMO business. The company continues a multi-year NanoAb collaboration with the Max Planck Society and University Medical Center Göttingen, including intradermal and systemic IL‑17 programs. The intradermal IL‑17 psoriasis program is the subject of an application under Poland’s FENG program for approximately €12 million in grant funding. On the CDMO side, Scinai reports approximately $3.1 million of Committed Customer Orders as of August 16, 2026 and is pursuing about $5 million of 2026 CDMO revenue, supported by an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical customer under an existing relationship while a broader definitive agreement is negotiated.
Scinai Immunotherapeutics Ltd. (SCNI) has filed a post-effective amendment to a Form F-1 to update the resale registration for up to 439,942 American Depositary Shares (ADSs), representing 17,597,680,000 Ordinary Shares, issuable to YA II PN, Ltd. under a $15.0 million Standby Equity Purchase Agreement signed on September 10, 2025. These ADSs are being registered for resale by YA as the selling shareholder; Scinai is not selling securities in this prospectus and will not receive proceeds from YA’s resales.
Scinai may, at its discretion, sell ADSs to YA as “Advance Shares” at a purchase price equal to 97% of the lowest of three daily VWAPs during a pricing period, subject to conditions and a 9.99% Ownership Limitation. To date, 36,512 ADSs have been sold to YA for approximately $100 thousand, leaving about $14.9 million of the commitment potentially available. As of August 23, 2026, there were 706,586 ADSs outstanding; if all 439,942 registered ADSs were issued and outstanding, they would represent about 38.37% of total ADSs as of that date, implying substantial potential dilution.
The filing also reflects a ratio change effective August 21, 2026, increasing each ADS from representing 4,000 to 40,000 Ordinary Shares, which had the same effect as a one-for-ten reverse ADS split and is intended in part to address Nasdaq’s minimum bid-price deficiency. Scinai highlights ongoing Nasdaq listing risks, prior equity restructuring (including conversion of EIB debt into preferred shares), and plans to use any future proceeds from YA for pipeline development, support of its CDMO business, and general corporate purposes.
Scinai Immunotherapeutics Ltd. (SCNI) reported results for the six months ended June 30, 2026, showing early scale-up of its CDMO-focused model but continued operating losses. Revenues were $0.95 million, up from $0.77 million a year earlier, driven largely by the February 2026 acquisition of Recipharm Israel Ltd. (now Scinai Biopharma Services Ltd.). The acquired Yavne CDMO business contributed about $0.65 million of revenue but generated a $2.06 million net loss over the partial period.
Cost of revenues rose to $3.32 million, leading to a gross loss of $2.37 million. With R&D expenses of $0.84 million and marketing, general and administrative expenses of $1.40 million, the operating loss reached $4.61 million. A one-time $6.40 million gain from bargain purchase on the Recipharm deal turned the period into a reported net profit of $1.57 million, but the core business remains loss-making.
Total assets increased to $17.18 million, including $2.85 million in cash, cash equivalents and restricted cash. Net cash used in operating activities was $3.92 million, partially offset by $2.64 million of net investing inflows (mainly acquisition cash) and $2.33 million from equity financings, including a $2.6 million ADS and warrant transaction. As of August 16, 2026, Scinai reported Committed Customer Orders of about $3.1 million across its Jerusalem and Yavne facilities and continues to pursue a $5.0 million 2026 CDMO revenue target, while acknowledging it may not be achieved. Management highlights a growing U.S. clinical manufacturing opportunity and ongoing NanoAbs and PC111 development, but also notes that CDMO operations currently run at a loss and that additional funding will be required to support operations and growth.
Scinai Immunotherapeutics Ltd. (SCNI) is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective August 21, 2026. Each ADS will represent 40,000 ordinary shares, instead of 4,000, which has the same effect as a one-for-ten reverse split of the ADSs.
SCNI’s ADSs are expected to begin trading on the Nasdaq Capital Market on an adjusted basis on August 21, 2026, continuing under the symbol SCNI with a new CUSIP 09073Q402. Holders do not need to take action; fractional ADS entitlements will be aggregated and sold, with net cash proceeds distributed by the depositary. The stated objective is to increase the per-ADS trading price and seek compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS, although the company notes there is no assurance this change will restore or maintain compliance.
LCK JNK 1 LLC reports beneficial ownership of 317,366 American Depository Shares (ADS), representing 6.33% of the class of ADS of Scinai Immunotherapeutics Ltd.
The filing shows the ADS class is structured as one ADS = 4,000 ordinary shares. The filing lists sole voting and dispositive power over 317,366 ADS. The document is signed by Richard J. Kertzman as Sole Member on 06/18/2026 and references 04/27/2026 in the cover area.
Scinai Immunotherapeutics Ltd. ownership update: Daniel E. Stone and RK Stone Miami, LLC filed an amendment reporting voting power and warrant positions. The filing lists sole voting power of 496,332 ADSs for Daniel E. Stone and 357,006 ADSs for RK Stone Miami, LLC. It cites 20,053,835,584 ordinary shares outstanding as of June 3, 2026 and notes a 9.99% beneficial ownership limitation tied to exercise of pre-funded warrants. The amendment records that on June 25, 2026 RK exercised 157,006 warrants and, as of that date, holds 357,006 ADSs plus 692,505 pre-funded warrants.
GERMAIN MARK reported acquisition or exercise transactions in this Form 4 filing.
Scinai Immunotherapeutics director Mark Germain received a large equity award of 120,000,000 Ordinary Shares on June 16, 2026. The shares were granted at no cash cost as restricted share units and will vest in three equal annual installments, subject to his continued service. After this grant, he directly holds 120,000,000 Ordinary Shares, which are represented by American Depositary Shares, with each ADS currently corresponding to 4,000 Ordinary Shares.
Reichman Amir reported acquisition or exercise transactions in this Form 4 filing.
Scinai Immunotherapeutics Ltd. reported that Chief Executive Officer Amir Reichman received a grant of 400,000,000 Ordinary Shares on June 16, 2026 as a stock award. The shares were granted at a per-share price of $0.00 and are represented by restricted share units (RSUs).
The 400,000,000 Ordinary Shares vest in three equal annual installments after the grant date, subject to his continued service. After this award, Reichman directly owns 711,637,600 Ordinary Shares, including RSUs granted on January 25, 2024 and December 22, 2025, each with its own multi-year vesting schedule. Each American Depositary Share currently represents 4,000 Ordinary Shares.